Paper7585609
ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer.
Szöllösi J and 4 others. Cancer Res, 1995. Cited by 113 papers, by iCite.
Cite this record
ConductScience Library. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Papers, record 7585609. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7585609
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Chromosomes, Human, Pair 17 | Major topic |
| Gene Dosage | Major topic |
| Genes, erbB-2 | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| DNA | |
| Female | |
| Gene Amplification | |
| Humans | |
| Tumor Cells, Cultured |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA-44768 | NCI NIH HHS | United States | P01CA044768 | PubMed and NIH | NIH RePORTER |
| CA-49056 | NCI NIH HHS | United States | R01CA049056 | PubMed and NIH | NIH RePORTER |
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 113 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40277788 | Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions. | Curr Oncol | 2025 | https://conductscience.org/library/papers/40277788 | PubMed |
| 39187701 | Predicting Pathological Characteristics of HER2-Positive Breast Cancer from Ultrasound Images: a Deep Ensemble Approach. | J Imaging Inform Med | 2025 | https://conductscience.org/library/papers/39187701 | PubMed |
| 38684051 | Nanoparticle Anisotropy Increases Targeting Interactions on Live-Cell Membranes. | ACS Nano | 2024 | https://conductscience.org/library/papers/38684051 | PubMed |
| 37238604 | Is Cancer Reversible? Rethinking Carcinogenesis Models-A New Epistemological Tool. | Biomolecules | 2023 | https://conductscience.org/library/papers/37238604 | PubMed |
| 35625590 | Paradoxical Behavior of Oncogenes Undermines the Somatic Mutation Theory. | Biomolecules | 2022 | https://conductscience.org/library/papers/35625590 | PubMed |
| 34775465 | Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. | Oncogenesis | 2021 | https://conductscience.org/library/papers/34775465 | PubMed |
| 34711990 | Direct targeting of amplified gene loci for proapoptotic anticancer therapy. | Nat Biotechnol | 2022 | https://conductscience.org/library/papers/34711990 | PubMed |
| 33262066 | Adoptive T cell therapy: Boosting the immune system to fight cancer. | Semin Immunol | 2020 | https://conductscience.org/library/papers/33262066 | PubMed |
| 32929653 | Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-ZHER2 affibody conjugate. | Mol Biol Rep | 2020 | https://conductscience.org/library/papers/32929653 | PubMed |
| 31423731 | Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics. | Cytometry A | 2020 | https://conductscience.org/library/papers/31423731 | PubMed |
| 31186729 | Differential expression of EphA5 protein in gastric carcinoma and its clinical significance. | Oncol Lett | 2019 | https://conductscience.org/library/papers/31186729 | PubMed |
| 30239581 | Revealing tumor heterogeneity of breast cancer by utilizing the linkage between somatic and germline mutations. | Brief Bioinform | 2019 | https://conductscience.org/library/papers/30239581 | PubMed |
| 29346397 | Dose enhancement effects of gold nanoparticles specifically targeting RNA in breast cancer cells. | PLoS One | 2018 | https://conductscience.org/library/papers/29346397 | PubMed |
| 29285221 | A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. | Oncotarget | 2017 | https://conductscience.org/library/papers/29285221 | PubMed |
| 28586395 | The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. | PLoS One | 2017 | https://conductscience.org/library/papers/28586395 | PubMed |
| 28208769 | Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28208769 | PubMed |
| 28110020 | Tumor evolution: Linear, branching, neutral or punctuated? | Biochim Biophys Acta Rev Cancer | 2017 | https://conductscience.org/library/papers/28110020 | PubMed |
| 27455875 | Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods. | J Mol Diagn | 2016 | https://conductscience.org/library/papers/27455875 | PubMed |
| 26696368 | In Vivo Autofluorescence Imaging of Tumor Heterogeneity in Response to Treatment. | Neoplasia | 2015 | https://conductscience.org/library/papers/26696368 | PubMed |
| 26330166 | Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. | Cancer Res | 2015 | https://conductscience.org/library/papers/26330166 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7585609
GET https://conductscience.org/api/papers/v1/7585609/cited_by?page=2